Amgen launches the Enbrel Mini single-dose prefilled cartridge with AutoTouch reusable autoinjector that is ergonomically designed for patients.

Amgen announced that the Enbrel Mini with AutoTouch is now available in the United States. Awarded the Arthritis Foundation Ease of Use Commendation, the new delivery system provides an additional administration option for appropriate Enbrel patients.

The AutoTouch reusable autoinjector has an ergonomic design that includes features that were designed with patients in mind, including an ergonomic handle, a needle designed to stay hidden during the injection, a sensor to detect placement on skin, a speed switch with three injection speeds, a progress bar and a speaker.

The AutoTouch reusable autoinjector is used with Enbrel Mini single-dose prefilled cartridges (50 mg/mL) that utilize a new drug formulation of Enbrel that was associated with substantially significant lower mean injection site pain than the current formulation.

Enbrel is an injectable biologic approved for the treatment of several chronic conditions including moderate-to-severe rheumatoid arthritis (RA), moderate-to-severe polyarticular juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and moderate-to-severe plaque psoriasis (PsO) in patients four years or older. 

The Enbrel Mini with AutoTouch was approved by the U.S. Food and Drug Administration in September 2017.

A Phase 3b multicenter, randomized, double-blind, crossover study was conducted to assess the injection site pain associated with a modified etanercept formulation in adult patients with either moderate-to-severe RA or PsA. In addition to demonstrating a significant reduction in injection site pain, the adverse events were similar to those seen in previous studies in adults with moderate-to-severe RA and PsA.

(Source: Amgen)